Stay updated on Tildrakizumab for Chronic Plaque Psoriasis Clinical Trial
Sign up to get notified when there's something new on the Tildrakizumab for Chronic Plaque Psoriasis Clinical Trial page.

Latest updates to the Tildrakizumab for Chronic Plaque Psoriasis Clinical Trial page
- Check4 days agoChange DetectedThe page now displays Revision: v3.3.3. References to HHS Vulnerability Disclosure and Revision: v3.3.2 have been removed.SummaryDifference0.1%

- Check11 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check33 days agoChange DetectedThe Publications section had minor editorial updates: wording about publications and PubMed sources was refined and the revision tag changed from v3.2.0 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check40 days agoChange DetectedThe funding-lapse notice stating that information may not be up to date and that the NIH Clinical Center may have limited responsiveness has been removed; the page no longer presents the cc.nih.gov and opm.gov references.SummaryDifference0.4%

- Check54 days agoChange DetectedStudy design, interventions, outcomes, eligibility criteria, and dates appear unchanged compared with the previous version. No new content or deletions affecting the core information on the Study Details page were detected.SummaryDifference0.3%

- Check83 days agoChange Detected- Updated operating-status notice and new version tag (v3.2.0) added; old version tag (v3.1.0) removed. The page now provides current status guidance and a newer software/document version.SummaryDifference1%

- Check90 days agoChange DetectedPage revision updated from v3.0.2 to v3.1.0, indicating a version bump with no other substantive content changes.SummaryDifference0.0%

Stay in the know with updates to Tildrakizumab for Chronic Plaque Psoriasis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Tildrakizumab for Chronic Plaque Psoriasis Clinical Trial page.